Dr. Pagidipati is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2301 Erwin Rd
Durham, NC 27705Phone+1 919-681-9660
Education & Training
Duke University HospitalFellowship, Cardiovascular Disease, 2013 - 2017
Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
Harvard Medical SchoolClass of 2008
Certifications & Licensure
NC State Medical License 2013 - 2025
MA State Medical License 2011 - 2014- American Board of Internal Medicine Cardiovascular Disease
Clinical Trials
- RESILIENCE: Personalizing Cardiovascular Health Start of enrollment: 2020 Sep 22
Publications & Presentations
PubMed
- 1233 citationsEffects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.Rury R. Holman, M. Angelyn Bethel, Robert J. Mentz, Vivian P. Thompson, Yuliya Lokhnygina
The New England Journal of Medicine. 2017-09-14 - 48 citationsEffect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL T...Marat Fudim, Jennifer White, Neha J. Pagidipati, Yuliya Lokhnygina, Julio Wainstein
Circulation. 2019-11-12 - 377 citationsCardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.M. Angelyn Bethel, Rishi A Patel, Peter Merrill, Yuliya Lokhnygina, John B. Buse
The Lancet. Diabetes & Endocrinology. 2017-12-06
Authored Content
- Reducing Cardiovascular Risk Following StrokeSeptember 2020
- An Outcome Model Approach to Transporting a Randomized Controlled Trial Results to a Target PopulationMarch 2019
Press Mentions
Updates from the SELECT Trial: Outcomes by Sex | ESC 2024August 30th, 2024- Insights from the FLOW Trial | ESC 2024August 30th, 2024
- New Science Suggests Semaglutide Improves CV Outcomes Beyond Weight LossAugust 30th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
